CARNELIAN CAPITAL COMPOUNDER STRATEGY
1,731.37 CR AUM
CARNELIAN CAPITAL COMPOUNDER STRATEGY
1,731.37 CR AUM

manoj bahety

kunal shah
Purpose
Carnelian Capital Compounder Strategy is a long only multi cap equity portfolio designed to capture the long term trillion dollar India opportunity by investing in quality growth companies at a reasonable price. The strategy builds a concentrated portfolio of about 25 listed companies selected for niche core competence, large opportunity size, strong governance and proven management capabilities. Investment philosophy follows a Quality Growth at a Reasonable Price framework combining quality business assessment, growth potential and reasonable valuation. The approach focuses on both accelerated earnings growth opportunities arising from catalysts such as management change, industry structure change, new growth catalysts, product innovation or completion of capex cycle and stable compounder businesses with sustainable moat, robust free cash flow generation and large opportunity size. A proprietary forensic framework called CLEAR evaluates cash flow analysis, liability analysis, earnings quality analysis, asset quality analysis and related party or governance issues to identify red flags and avoid governance risks. Portfolio holdings illustrating the strategy include companies such as Aditya Birla Capital, Biocon, Laurus Labs, One 97 Communications, Tech Mahindra, Larsen and Toubro, BHEL, Punjab National Bank, Yatharth Hospital and Maruti Suzuki, representing businesses benefiting from structural growth opportunities in the Indian economy. Sector agnostic. Market cap combination of small cap, mid cap and large cap.
Investment Approach v/s Benchmark Metrics
Unlock all metrics
Login to see the live performance and return
Wealth Creation Calculator
Investment Approach v/s Benchmark Performance
Unlock all metrics
Login to see the live performance and return